MET and lung cancer: Indeed, in the section titled “emerging biomarkers to identify novel therapies for patients with metastatic NSCLC”, they included high-level MET amplification as a genetic alteration (i.e., driver event) and indicated that available targeted agents with activity against driver events in lung cancer are capmatinib, tepotinib, and crizotinib [3,93].